hSMG-1 inhibitor 11e | whatman (沃特曼)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

hSMG-1 inhibitor 11e 纯度: 99.18%

hSMG-1 inhibitor 11e 是一种有效的选择性的 hSMG-1 激酶抑制剂，其 IC₅₀ 值 <0.05 nM。hSMG-1 inhibitor 11e 对 hSMG-1 的选择性比 mTOR (IC₅₀ 为 45 nM)，PI3Kα/γ (IC₅₀ 为 61 nM 和 92 nM) 和 CDK1/CDK2 (IC₅₀ 为 32 μM 和 7.1 μM) 高 900 倍。

hSMG-1 inhibitor 11e Chemical Structure

CAS No. : 1402452-10-1

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥5470	In-stock
5 mg	￥4800	In-stock
10 mg	￥8000	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

hSMG-1 inhibitor 11e 相关产品

•相关化合物库:

Covalent Screening Library Plus
Bioactive Compound Library Plus
Cell Cycle/DNA Damage Compound Library
Kinase Inhibitor Library
PI3K/Akt/mTOR Compound Library
Stem Cell Signaling Compound Library
Anti-Cancer Compound Library
Autophagy Compound Library
Anti-Aging Compound Library
Covalent Screening Library
Antioxidants Compound Library
Differentiation Inducing Compound Library
Reprogramming Compound Library
Oxygen Sensing Compound Library
Glycolysis Compound Library
Cytoskeleton Compound Library
Anti-Breast Cancer Compound Library
Anti-Lung Cancer Compound Library
Anti-Pancreatic Cancer Compound Library
Anti-Blood Cancer Compound Library
Anti-Cancer Metabolism Compound Library
Angiogenesis Related Compound Library
Glucose Metabolism Compound Library
Anti-Liver Cancer Compound Library
Anti-Colorectal Cancer Compound Library

生物活性

hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC₅₀ of <0.05 nM. hSMG-1 inhibitor 11e shows >900-fold selectivity over mTOR (IC₅₀ of 45 nM), PI3Kα/γ (IC₅₀s of 61 nM and 92 nM) and CDK1/CDK2 (IC₅₀s of 32 μM and 7.1 μM)^[1].

IC₅₀ & Target^[1]

mTOR

45 nM (IC₅₀)

PI3Kα

61 nM (IC₅₀)

PI3Kγ

92 nM (IC₅₀)

CDK1

32 μM (IC₅₀)

CDK2

7.1 μM (IC₅₀)

hSMG-1

<0.05 nM (IC₅₀)

体外研究
(In Vitro)

hSMG-1 kinase plays a dual role in a highly conserved RNA surveillance pathway termed nonsense-mediated RNA decay (NMD) and in cellular genotoxic stress response. Since deregulation of cellular responses to stress contributes to tumor growth and resistance to chemotherapy, hSMG-1 is a potential target for cancer treatment^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

517.60

Formula

C₂₆H₂₇N₇O₃S

CAS 号

1402452-10-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶解性数据

In Vitro:

DMSO : 50 mg/mL (96.60 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9320 mL	9.6600 mL	19.3199 mL
5 mM	0.3864 mL	1.9320 mL	3.8640 mL
10 mM	0.1932 mL	0.9660 mL	1.9320 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 5 mg/mL (9.66 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (9.66 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: 5 mg/mL (9.66 mM); Suspended solution; Need ultrasonic

此方案可获得 5 mg/mL (9.66 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Ariamala Gopalsamy, et al. Identification of pyrimidine derivatives as hSMG-1 inhibitors. Bioorg Med Chem Lett. 2012 Nov 1;22(21):6636-41.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务